Background: The incidence of tumor lysis syndrome (TLS) has been reported in 42% of adults with hematologic malignancies and can result in serious laboratory findings and clinical manifestations. The clinical manifestations may be severe, leading to dialysis therapy and/or death. The exact incidence of these severe outcomes has not been determined; however, strategies to determine the risk for these complications have been proposed.

Background: Glioblastoma multiforme (GBM) is a highly malignant glial tumor characterized by rapid growth and angiogenesis. Current frontline therapy consists of surgical resection, radiation, and chemotherapy; however, all patients will progress. Over the past decade, there have been increases in the quality and quantity of clinical data regarding the treatment of patients with GBM.

Background: Oral chemotherapy has an ever-increasing role in the treatment of patients with cancer, but high cost increases the risk for primary nonadherence or “nonfulfillment.” Non-fulfillment is defined as failure to obtain a prescribed medication. Proven methods to decrease nonfulfillment rates for oral chemotherapy are lacking in the literature.

Inotuzumab Ozogamicin Shows High Response Rate in Refractory/Relapsed ALL

Background: Patients with refractory or relapsed acute lymphoblastic leukemia (ALL) have a poor prognosis. Inotuzumab ozogamicin is a monoclonal antibody against CD22, which is highly expressed on the surface of leukemic cells in patients with ALL. Studies with other monoclonal antibodies against CD22 or other surface antigens have shown encouraging activity in patients with ALL.


Results 1 - 4 of 4